Anterior chamber phakic IOL [the phakic 6] in the treatment of myopia and hypermetropia: 5-year follow-up

The aim of this study is to evaluate the efficacy and safety of anterior chamber phakic intraocular lenses in correcting high myopia and hypermetropia using the Safety Flex Phakic 6 anterior chamber intraocular lens [AC-IOL]. The study included 32 eyes [24 myopes and 8 hypermetropes]. The age ranged from 20 to 45 years. They we all phakic, with intact accommodation. They all underwent implantation of the Phakic 6 AC-IOL and they were followed-up for 5 years. Correction of the refractive error was achieved with a mean postoperative refractive error of -1.34D after one year which dropped to -1.95D after 5 years, and improvement of best corrected visual acuity was 17%. There were no significant complications and a high safety profile was achieved in the follow-up period. The phakic 6 proved to be a safe and effective method of correcting high myopia and hypermetropia according to the results of our study

Endothelial changes after angle supported anterior chamber phakic IOL'S

Purpose: To evaluate the endothelial changes after implantation of the Safety Flex Phakic 6 TM angle supported anterior chamber phakic IOL. Design: Noncomparative case series. Participants: 42 eyes [28 myopes and 14 hyperopes]. Methodology: Specular microscopy was done preoperatively and after implantation of the IOL at 1, 3, 6, 9 months and one year intervals. Main Outcome Measures: Significant endothelial cell loss [50% of the original count] is an indication for explantation. The central cell loss caused by the operation is approximately 3.6%; with time, this cell loss increases to 5.7% after one year. The peripheral cell loss caused by the operation is approximately 3.42%; with time, this cell loss increases to 3.9 1% after one year. The Safety Flex Phakic 6 TM was an effective and safe method for correcting myopia and hyperopia with safe and accepted endothelial cell loss after one year